Medications

Migraines are a common ailment worldwide, affecting nearly 15% of the global population. At times, they can be debilitating enough to interfere with daily activities. Despite a multitude of treatment options, some migraine sufferers cannot find relief in available drugs. Others experience side effects that prevent the use of certain available migraine medications.

Imagine a drug that halts cancer without side effects or risks. That future may be a bit nearer thanks to recent research led by Raj Kumar, Ph.D., chair of the Department of Pharmaceutical and Biomedical Sciences at Touro College of Pharmacy.

Simon Fraser University researchers are using a new approach to brain imaging that could improve how drugs are prescribed to treat Parkinson’s disease.

A drug commonly used to treat type 2 diabetes may reduce excess fluid in the brains of patients with hydrocephalus, which could help treat the disease less invasively than current treatments, according to a Northwestern Medicine study published in the Journal of Clinical Investigation.

A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating side effect.

GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with fat.

Researchers at the Case Western Reserve School of Medicine have found that semaglutide, a popular diabetes and weight-loss drug, may lower the risk of dementia in people with type 2 diabetes (T2D).

The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with relapsed or refractory follicular lymphoma.

For adults with obesity or overweight without diabetes, the novel cyclic adenosine monophosphate-biased glucagon-like peptide 1 receptor agonist known as ecnoglutide yields a superior and sustained reduction in body weight versus placebo, according to a study published online June 21 in The Lancet Diabetes & Endocrinology to coincide with the annual meeting of the American Diabetes Association, held from June 20 to 23 in Chicago.

Acute myocarditis—sudden inflammation of the heart—causes mild symptoms in most cases, but about 10% of acute myocarditis cases can be sudden and severe, leading to cardiac arrhythmias, heart pump failure, or even death. Current therapies for the condition are built on limited data and may not effectively target the underlying disease mechanisms. Patients may even require mechanical circulatory support for life support when the heart is failing.